ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / ANGO / earnings
SENS (40) SGHT (39) DCTH (59) TCMD (67) ⌘ Pro Terminal →

AngioDynamics Inc. (ANGO) Next Earnings Date & Expected ±11.6% Move

$11.99 -2.91% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $11.90

AngioDynamics Inc. (ANGO) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D- • RED ALERT Cap $504.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ANGO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ANGO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, AngioDynamics Inc. (NASDAQ: ANGO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $11.99 (-2.91% 1D, market cap $504.2M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ANGO ranks #566 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ANGO compare to SENS and SGHT in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), ANGO carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 54.6%, and ROIC of -23.4%. By comparison, SENS (Senseonics Holdings Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $502.8M) and SGHT (Sight Sciences Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $513.4M). Among the 5-stock peer group, TCMD leads on earnings multiple (28.9x) while TCMD leads on capital efficiency (17.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ANGO?
▼

Per ANGO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-05-31, CIK 0001275187), AngioDynamics Inc. generated $320.2M in revenue (+9.5% YoY), -$36.7M in net income, and $508.0K in free cash flow against $269.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $11.90 (-0.71%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0.2% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510036
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (10)Whales (5)SEC (10)Macro (6)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-9.9% Base Target
$17 Bull$11 Base$8 Bear
📬 FREE ANGO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ANGO)Realized 20D OHLCV Swing Band: ±11.6%
Deterministic 5-Pillar Attribution (36/100 Composite)
🔍 WHY ANGO SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+10/20 pts (28% of score)

SEC XBRL FY 2025 (10-K): 0.2% FCF Margin ($508.0K FCF) & 54.6% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)

Altman Z-Score 2.12 (WATCH ZONE (1.8–3.0)) • Piotroski F-Score 6/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
28
Grade E$10.90+8.3% Next Q
Q2 (-2Q)
31
Grade E$11.81+3.8% Next Q
Q3 (-1Q)
33
Grade E$12.26-2.2% Next Q
Current
36
Grade D-$11.99-8.3% Hist 90D α
Trajectory: E (28) → D- (36)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ANGO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ANGO currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($14.04) and Max Pain ($12.59) forces dealer call-delta covering toward $17.10.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ANGO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ANGO Beats Next Quarter EPS Consensus (Nov 29, 2026) & Holds Above 200D SMA”
YES 36%NO 64%Trade / Inspect Odds →
NEXT EST. WINDOW: Nov 29, 2026 (~26 DAYS)

Historical OHLCV Volatility ±11.6% Swing Band

±$1.39 Expected Swing
$10.60 (-11.6%)Spot $11.99$13.38 (+11.6%)
MODEL EARNINGS SETUP GAUGE

ANGO Quantitative Pre-Earnings Setup: 36/100

Trailing EPS: $4.25 • YoY Revenue Growth: 9.5%

Model Bullish Setup (36/100)Model Risk Weight (64/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252026-05-31$320.2M-$36.7M$508.0K54.6%
FY 20242025-05-31$292.5M-$34.0M-$14.6M53.9%
FY 20232024-05-31$303.9M-$184.3M-$28.2M54.6%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ANGO)

  • ✓Walkthrough of ANGO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ANGO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +9.20%📐 HORIZONTAL RANGE
2026-11-03O $12.35H $12.35L $11.99C $11.99VOL 475.8K
RES: $17.74SUP: $10.44SMA50: $14.04SMA200: $12.49
$16.69$15.04$13.40$11.75$10.11RES $17.74SUP $10.44$11.992026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ANGO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ANGO Butterfly Map → + Track ANGO →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +9.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ANGO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ANGO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ANGO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ANGO)

Health Care Rank #566 of 1016 ⚔️ SENS vs ANGO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ANGO vs. SENS, SGHT, DCTH, TCMD)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, AngioDynamics Inc. (ANGO) ranks #566 by composite RQD confidence (36/100, grade D-) and #441 by equity capitalization ($504.2M). Within this direct 5-issuer industry benchmark cohort, TCMD leads on earnings valuation at 28.9x trailing P/E, while TCMD leads on capital efficiency and profitability with 17.1% ROIC and 75.9% gross margin. TCMD currently holds the highest overall quantitative score in the immediate peer group at 67/100 (C+) compared with ANGO at 36/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ANGO ACTIVE
AngioDynamics Inc.
D- 36/100 — 54.6% -23.4% -2.91% $504.2M Benchmark Subject
SENS
Senseonics Holdings Inc.
D- 40/100 — 44.7% -35.0% -2.46% $502.8M /sens-vs-ango →
SGHT
Sight Sciences Inc.
D- 39/100 — 86.2% -35.0% -2.61% $513.4M /sght-vs-ango →
DCTH
Delcath Systems Inc.
C- 59/100 — 86.2% 0.8% -4.10% $487.2M /dcth-vs-ango →
TCMD
Tactile Systems Technology Inc.
C+ 67/100 28.9x 75.9% 17.1% -5.22% $521.9M /tcmd-vs-ango →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-05-31 • CIK 0001275187

In its most recent audited fiscal period (FY2025, filed 2026-05-31), AngioDynamics Inc. (ANGO) reported GAAP revenue of $320.2M (+9.5% vs. FY2024 revenue of $292.5M , and +5.4% cumulative change since FY2023) , GAAP net income of -$36.7M, operating cash flow of $3.1M, and free cash flow of $508.0K (+103.5% YoY). On the balance sheet, ANGO closed FY2025 with $269.7M in total assets against $0 in total debt (Altman Z-Score: 2.12, Piotroski F-Score: 6/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2026-05-31 $320.2M -$36.7M $3.1M $508.0K $269.7M —
FY2024 (FY) 2025-05-31 $292.5M -$34.0M -$10.1M -$14.6M $291.6M —
FY2023 (FY) 2024-05-31 $303.9M -$184.3M -$28.2M -$28.2M — —

3. ANGO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ANGO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, AngioDynamics Inc. (NASDAQ: ANGO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $11.99 (-2.91% 1D, market cap $504.2M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ANGO ranks #566 in composite RQD confidence.

How does ANGO compare to SENS and SGHT in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), ANGO carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 54.6%, and ROIC of -23.4%. By comparison, SENS (Senseonics Holdings Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $502.8M) and SGHT (Sight Sciences Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $513.4M). Among the 5-stock peer group, TCMD leads on earnings multiple (28.9x) while TCMD leads on capital efficiency (17.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ANGO?

Per ANGO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-05-31, CIK 0001275187), AngioDynamics Inc. generated $320.2M in revenue (+9.5% YoY), -$36.7M in net income, and $508.0K in free cash flow against $269.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ANGO trading relative to its 50-day, 200-day, and 52-week technical levels?

ANGO last traded at $11.99 (-2.91% on volume of 475,847 shares), positioning the stock -14.60% below its 50-day simple moving average ($14.04) and -4.00% below its 200-day simple moving average ($12.49). Across its 52-week range of $9.39 to $16.29, ANGO sits at the 37.7% percentile with a 14-day RSI of 40.8 (NEUTRAL RANGE) and an implied next-earnings move of ±11.6% ($10.60 to $13.38).

ANGO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is ANGO's next earnings date?

Based on SEC filing cadence, AngioDynamics Inc. (ANGO)'s next quarterly reporting window is estimated around Nov 29, 2026.

How much is ANGO stock expected to move on earnings?

Volatility modeling currently projects a ±11.6% event move for ANGO, spanning a range between $10.6 and $13.38.

Direct Sub-Reports: ANGO RQD Cockpit ANGO 12M Forecast ANGO Earnings & Move ANGO Dividends & DRIP ANGO Insiders & 13F ANGO Whale Options ANGO Profit Sankey ANGO News & Why
ROARABLE RATING BRIEF • RQD 36/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ANGO — AngioDynamics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:35:28Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ANGO scores 36 out of 100 with a letter grade of D- and a verdict label of "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars, the Fundamental Cash Engine scores 10 of 20 (ROIC of -23.4% and FCF yield of 0.1%), indicating that the business is not currently generating returns on invested capital. Whale/13F Flow scores 5 of 20 and Insider Conviction scores 5 of 20, signaling weak institutional and insider support in the source data; the Butterfly graph and analyst/holder sections contain no further detail on these flows. Macro Regime Fit scores 6 of 20 with a beta of 1.0. Forensic Balance Sheet scores 10 of 20, reflecting an Altman Z-Score of 2.12, a Piotroski F-Score of 6/9, and a Debt/Equity ratio of 0.5. For a prospective investor, the upside case rests on a turnaround in operating economics from current negative margins; the valuation tradeoff is that earnings-based multiples are not available in source data, so value cannot be anchored to profitability, and the low FCF yield means little current cash return to shareholders. The balance-sheet metrics provide some staying power, but the combined rating points to elevated fundamental and flow risk.

Business

AngioDynamics Inc. (ANGO) is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry. Per the profile, the company has a market capitalization of $0.5B. Per the market data, gross margin is 54.6%, indicating that the company retains a substantial share of revenue after direct costs. Not available in source data for product lines, customer segments, or specific revenue-generation mechanics beyond the reported revenue figures.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$320.2M$-39.9M$-36.7MN/A$0.5M$41.6MN/A
FY 2024$292.5M$-40.0M$-34.0MN/A$-14.6M$54.1MN/A
FY 2023$303.9M$-192.4M$-184.3MN/A$-28.2MN/AN/A

Per the SEC financials, revenue rose from $292.5M in FY 2024 to $320.2M in FY 2025, while operating income remained negative in each reported period. Per the market data, operating margin is -12.5%, net margin is -11.5%, and ROIC is -23.4%. Per the Roarable RQD rating, the Altman Z-Score is 2.12 and the Piotroski F-Score is 6/9, with Debt/Equity at 0.5. Cash declined from $54.1M in FY 2024 to $41.6M in FY 2025 per the SEC financials.

Recent Catalysts & News Wire Analysis

  • Market wire (YELLOW): Yahoo Finance UK coverage of ANGO market action, institutional positioning, and fundamental catalysts (1h ago).
  • Risk watch (YELLOW): The Motley Fool, "Why AngioDynamics Crashed Today" (3h ago).
  • Risk watch (RED): Yahoo Finance, "AngioDynamics (ANGO) Reports Q1 Loss, Lags Revenue Estimates" (6h ago).
  • Market wire (YELLOW): Seeking Alpha, AngioDynamics 2027 Q1 earnings call presentation dated 2026-10-08 (9h ago).
  • Risk watch (RED): Simply Wall St, "AngioDynamics (ANGO) Stock Price Sinks As Losses Cloud Med Tech Progress" (12h ago).
  • Catalyst (GREEN): Investing.com, Canaccord reiterating its stock rating on growth platforms (15h ago).

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. The news items carry light classifications of YELLOW, RED, and GREEN as shown; the summaries are generic and do not specify the underlying figures.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, no upstream or downstream dependencies, butterfly links, or proprietary signals are recorded. Sector: Health Care; industry: Medical/Dental Instruments. Not available in source data for sector correlations or 2nd-order bottlenecks. Investors should note that the absence of mapped links is itself a data gap rather than evidence of independence.

Open Questions

  • What drove the negative operating income in each reported period, and what is the trajectory toward profitability?
  • What are the drivers of the cash decline from $54.1M to $41.6M, and what is the company's debt position, given that debt is listed as N/A?
  • Why are EPS and forward/TTM earnings multiples unavailable, and what would a valuation anchored to cash flow or sales look like?
  • What institutional, insider, and options positioning underlies the 5/20 whale and insider pillar scores?
  • What specific catalysts or risks are described in the Q1 loss and earnings-call coverage?

ANGO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for AngioDynamics Inc. (ANGO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ANGO Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ANGO Bull vs. Bear Conversation Board — What's Your Call at $11.99?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ANGO 🐻 67% BEARISH CONVICTION
1. Pick Your Side on ANGO:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $10.87 (-12.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ANGO (D- • RQD 36/100) a Buy at $12.35?

Welcome to the ANGO (AngioDynamics Inc.) Roar Pit. Current RQD Composite is 36/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $9.26 (-25.0%)
Spot @ $12.35

Pump the brakes on ANGO — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ANGO, but look at what you are paying: current EV/EBITDA multiples with 54.6% gross margins. Unless AngioDynamics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $14.57 (+18.0%)
Spot @ $12.35

ANGO cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ANGO, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $12.35 (52-wk range $9.39 - $16.29), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%